Reduction of Fe(III) is required for uptake of nonheme iron by Caco-2 cells.
Differentiated cultures of Caco-2 human colonic cells were used to examine the importance of reduction of nonheme ferric iron, Fe(III), for transport across the brush border surface. Cultures accumulated approximately 100 pmol Fe/(h.mg protein) when 10 mumol Fe(III) as the nitrilotriacetic acid complex (1Fe:2NTA) was added to the apical compartment. Ascorbic acid enhanced cellular acquisition of iron in a dose-dependent manner, with a concentration as low as 8 mumol/L ascorbate increasing iron uptake by 50%. Similarly, the rate of iron transport from the apical to the basolateral compartment increased 5.6- and 30-fold when 100 and 1000 mumol/L ascorbic acid, respectively, were present in the apical chamber. Ascorbate-mediated stimulation of iron uptake was temperature dependent and required the reduction of Fe(III) to Fe(II), because it was inhibited by ascorbate oxidase and chelators of Fe(II). Moreover, Caco-2 cells recycled dehydroascorbic acid to ascorbic acid. Ferricyanide and Fe(II) chelators also partially inhibited iron uptake from a medium devoid of ascorbic acid. Intact Caco-2 cells exhibited a ferrireductase activity on the apical surface that accounted for the majority of iron accumulated by cells incubated in the absence of exogenous reductant. These data suggest that reduction of Fe(III) within the lumen or at the cell surface is required for transfer of this essential micronutrient across the intestinal brush border surface.
Han
O
O
Department of Food, Nutrition and Food Service Management, University of North Carolina, Greensboro 27412, USA.
Failla
M L
ML
Hill
A D
AD
Morris
E R
ER
Smith
J C
JC
D001205:Ascorbic Acid / Q000494:pharmacology*; D001692:Biological Transport / Q000187:drug effects; D002460:Cell Line; D003106:Colon / Q000166:cytology / Q000201:enzymology / Q000378:metabolism* / Q000648:ultrastructure; D004305:Dose-Response Relationship, Drug; D038181:FMN Reductase; D005290:Ferric Compounds / Q000378:metabolism* / Q000493:pharmacokinetics; D005296:Ferrous Compounds / Q000378:metabolism* / Q000493:pharmacokinetics; D006801:Humans; D008871:Microvilli / Q000378:metabolism; D009247:NADH, NADPH Oxidoreductases / Q000502:physiology; D010084:Oxidation-Reduction
D005290:Ferric Compounds; D005296:Ferrous Compounds; D038181:FMN Reductase; D009247:NADH, NADPH Oxidoreductases; C023903:ferric citrate iron reductase; D001205:Ascorbic Acid